Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

R. K. Murthy*, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. A. Hurvitz, N. U. Lin, V. Borges, V. Abramson, C. Anders, P. L. Bedard, M. Oliveira, E. Jakobsen, T. Bachelot, S. S. Shachar, V. Muller, S. Braga, F. P. Duhoux, R. Greil, D. CameronL. A. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. C. Palanca-Wessels, L. Walker, W. Feng, E. P. Winer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

795 Scopus citations

Fingerprint

Dive into the research topics of 'Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences